絞り込み

16506

広告

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study.

著者 Skinner KE , Fernandes AW , Walker MS , Pavilack M , VanderWalde A
J Med Econ.2017 Oct 18 ; ():1-9.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (33view , 0users)

Full Text Sources

Miscellaneous

To assess healthcare costs during treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with advanced non-small cell lung cancer (NSCLC).
PMID: 29041833 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード